Hearing loss: The final frontier of pharmacology
Abstract Despite a prevalence greater than cancer or diabetes, there are no currently approved drugs for the treatment of hearing loss. Research over the past two decades has led to a vastly improved understanding of the cellular and molecular mechanisms in the cochlea that lead to hearing deficits...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | Pharmacology Research & Perspectives |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/prp2.970 |
| _version_ | 1818471057080713216 |
|---|---|
| author | Alan C. Foster Bonnie E. Jacques Fabrice Piu |
| author_facet | Alan C. Foster Bonnie E. Jacques Fabrice Piu |
| author_sort | Alan C. Foster |
| collection | DOAJ |
| description | Abstract Despite a prevalence greater than cancer or diabetes, there are no currently approved drugs for the treatment of hearing loss. Research over the past two decades has led to a vastly improved understanding of the cellular and molecular mechanisms in the cochlea that lead to hearing deficits and the advent of novel strategies to combat them. Combined with innovative methods that enable local drug delivery to the inner ear, these insights have paved the way for promising therapies that are now under clinical investigation. In this review, we will outline this renaissance of cochlear biology and drug development, focusing on noise, age‐related, and chemotherapy‐induced hearing dysfunction. |
| first_indexed | 2024-04-13T21:45:57Z |
| format | Article |
| id | doaj.art-1036fd893f9c47e386b1eec0c643bfd5 |
| institution | Directory Open Access Journal |
| issn | 2052-1707 |
| language | English |
| last_indexed | 2024-04-13T21:45:57Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pharmacology Research & Perspectives |
| spelling | doaj.art-1036fd893f9c47e386b1eec0c643bfd52022-12-22T02:28:33ZengWileyPharmacology Research & Perspectives2052-17072022-06-01103n/an/a10.1002/prp2.970Hearing loss: The final frontier of pharmacologyAlan C. Foster0Bonnie E. Jacques1Fabrice Piu2Otonomy, Inc. San Diego California USAOtonomy, Inc. San Diego California USAOtonomy, Inc. San Diego California USAAbstract Despite a prevalence greater than cancer or diabetes, there are no currently approved drugs for the treatment of hearing loss. Research over the past two decades has led to a vastly improved understanding of the cellular and molecular mechanisms in the cochlea that lead to hearing deficits and the advent of novel strategies to combat them. Combined with innovative methods that enable local drug delivery to the inner ear, these insights have paved the way for promising therapies that are now under clinical investigation. In this review, we will outline this renaissance of cochlear biology and drug development, focusing on noise, age‐related, and chemotherapy‐induced hearing dysfunction.https://doi.org/10.1002/prp2.970cochleahair cellhearing lossneurotrophinototoxicityregeneration |
| spellingShingle | Alan C. Foster Bonnie E. Jacques Fabrice Piu Hearing loss: The final frontier of pharmacology Pharmacology Research & Perspectives cochlea hair cell hearing loss neurotrophin ototoxicity regeneration |
| title | Hearing loss: The final frontier of pharmacology |
| title_full | Hearing loss: The final frontier of pharmacology |
| title_fullStr | Hearing loss: The final frontier of pharmacology |
| title_full_unstemmed | Hearing loss: The final frontier of pharmacology |
| title_short | Hearing loss: The final frontier of pharmacology |
| title_sort | hearing loss the final frontier of pharmacology |
| topic | cochlea hair cell hearing loss neurotrophin ototoxicity regeneration |
| url | https://doi.org/10.1002/prp2.970 |
| work_keys_str_mv | AT alancfoster hearinglossthefinalfrontierofpharmacology AT bonnieejacques hearinglossthefinalfrontierofpharmacology AT fabricepiu hearinglossthefinalfrontierofpharmacology |